ALIA 1758
Alternative Names: ALIA-1758Latest Information Update: 28 Jun 2024
At a glance
- Originator Janssen
- Developer Aliada Therapeutics
- Class Antidementias; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 10 May 2024 Aliada Therapeutics plans a phase I trial for Alzheimer Disease (In volunteers) in USA (IV, SC, Injection) (NCT06406348)
- 09 May 2024 Phase-I clinical trials in Alzheimer's disease (In volunteers, In adults) in USA (IV) (NCT06406348)
- 09 May 2024 Phase-I clinical trials in Alzheimer's disease (In volunteers, In adults) in USA (SC) (NCT06406348)